• Home
  •  / Alimera Sciences

Alimera Sciences

OverviewSuggest Edit

Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is focused on diseases affecting the back of the eye, or retina. It provides ILUVIEN (fluocinolone acetonide intravitreal implant) for the treatment of diabetic macular edema (DME).
TypePublic
Founded2003
HQAlpharetta, GA, USMap
Websitealimerasciences.com
Employee Ratings3.8More
Overall CultureB-More
View Jobs (33)

Recent NewsAll News

Latest Updates

Employees (est.) (Jan 2020)122(-1%)
Job Openings33
Revenue (FY, 2020)$50.8 M(-5%)
Share Price (Jun 2021)$10.3
Cybersecurity ratingBMore

Key People/Management at Alimera Sciences

Ken Greene

Ken Greene

CSO
Rick Eiswirth

Rick Eiswirth

Director, President and Chief Executive Officer
Susan Caballa

Susan Caballa

Sr. Vice President, Regulatory & Medical Affairs
Brian Halak

Brian Halak

Director
Philip Ashman

Philip Ashman

Chief Operating Officer Senior Vice President, Commercial Operations Europe
Phil Jones

Phil Jones

Chief Financial Officer
Show more

Alimera Sciences Office Locations

Alimera Sciences has offices in Alpharetta, Berlin, Dublin 2, Lisboa and in 1 other location
Alpharetta, GA, US (HQ)
6120 Windward Pkwy #290
Berlin, DE
21 Cicerostraße
Dublin 2, IE
block c, Fitzwilliam Business Centre, 77 Sir John Rogerson's Quay, Dublin Docklands
Lisboa, PT
Avenida D. João II, 50 Edificio, R. do Mar Vermelho
Hampshire, GB
Wellesley Rd
Show all (5)

Alimera Sciences Financials and Metrics

Alimera Sciences Revenue

Alimera Sciences's revenue was reported to be $50.82 m in FY, 2020
USD

Revenue (FY, 2020)

50.8m

Net income (FY, 2020)

(5.3m)

EBIT (FY, 2020)

(501.0k)

Market capitalization (7-Jun-2021)

71.0m

Closing stock price (7-Jun-2021)

10.3

Cash (31-Dec-2020)

11.2m

EV

104.2m
Alimera Sciences's current market capitalization is $71 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.9m8.4m22.4m34.3m35.9m47.0m53.9m50.8m

Revenue growth, %

350%166%53%

Cost of goods sold

1.9m1.4m1.8m2.3m3.4m4.7m

Gross profit

9.0k7.0m20.7m32.0m32.5m42.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

179.0k758.0k2.1m2.2m2.4m3.9m5.8m6.9m5.8m9.6m8.3m6.6m10.4m9.8m9.8m10.9m11.1m12.9m10.9m12.9m14.5m10.0m12.5m

Cost of goods sold

11.0k57.0k564.0k376.0k372.0k283.0k376.0k634.0k378.0k556.0k486.0k587.0k769.0k1.0m1.3m1.1m965.0k1.6m

Gross profit

168.0k701.0k1.5m1.8m2.0m3.7m5.4m6.3m5.4m9.0m7.8m6.0m9.6m8.7m8.5m9.8m10.2m11.3m

Gross profit Margin, %

94%92%73%83%85%93%93%91%93%94%94%91%93%89%87%90%91%88%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

33.1m49.6m12.6m76.7m31.1m31.0m24.1m13.0m9.4m11.2m

Accounts Receivable

500.0k850.0k9.8m13.8m11.4m17.3m19.3m17.2m

Prepaid Expenses

692.0k2.0m3.5m3.2m2.7m2.3m2.1m2.6m3.7m

Inventories

719.0k1.8m1.7m1.6m446.0k1.5m2.4m1.4m2.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

43.9m38.1m27.6m22.3m17.4m39.3m31.9m23.1m41.3m42.0m61.4m61.3m48.1m39.3m23.9m16.6m33.9m26.7m26.9m25.6m20.3m16.7m12.6m13.1m12.2m7.9m12.2m13.5m11.3m

Accounts Receivable

129.0k464.0k1.3m1.0m1.1m3.4m7.7m9.4m9.1m13.3m13.4m10.8m13.6m13.5m12.4m13.4m14.3m15.4m13.9m16.4m16.2m14.0m15.6m

Prepaid Expenses

954.0k1.2m742.0k938.0k1.5m2.6m3.2m3.2m2.6m2.2m2.9m3.1m2.5m2.8m3.5m3.4m2.1m2.6m2.8m2.0m2.3m2.8m2.5m2.7m2.2m2.5m2.9m3.2m

Inventories

206.0k671.0k1.1m1.8m3.0m1.2m1.4m1.7m2.1m1.6m1.7m1.4m1.2m913.0k802.0k1.1m1.7m1.2m2.1m1.7m1.9m2.1m1.6m1.2m2.0m2.5m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(22.5m)(19.7m)(46.2m)(35.9m)(30.6m)(33.2m)(22.0m)(16.4m)(10.4m)(5.3m)

Depreciation and Amortization

133.0k106.0k138.0k659.0k2.6m2.8m2.7m2.6m2.6m2.7m

Inventories

(719.0k)(1.4m)(135.0k)(386.0k)1.0m(1.1m)(933.0k)996.0k(1.3m)

Accounts Payable

271.0k25.0k(259.0k)3.0m(487.0k)1.1m644.0k556.0k779.0k106.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(9.9m)(16.4m)(4.4m)(9.1m)(14.5m)(14.0m)(30.3m)(31.5m)(20.8m)(19.6m)(26.7m)(9.8m)(18.4m)(19.9m)(11.1m)(18.0m)(27.2m)(6.7m)(9.5m)(14.8m)(7.7m)(11.7m)(15.1m)(2.8m)(7.8m)(10.9m)(1.2m)(3.7m)(4.4m)

Depreciation and Amortization

79.0k106.0k26.0k53.0k80.0k27.0k59.0k101.0k36.0k69.0k151.0k558.0k1.2m1.9m689.0k1.4m2.1m666.0k1.3m2.0m649.0k1.3m1.9m652.0k1.3m2.0m654.0k1.3m2.0m

Inventories

(206.0k)(671.0k)(339.0k)(1.1m)(2.2m)548.0k400.0k(9.0k)(455.0k)(16.0k)(88.0k)164.0k301.0k612.0k(361.0k)(719.0k)(1.3m)299.0k(651.0k)(250.0k)532.0k256.0k726.0k177.0k(582.0k)(1.1m)

Accounts Payable

(246.0k)273.0k(292.0k)(669.0k)(854.0k)367.0k1.1m717.0k111.0k122.0k1.3m272.0k(1.2m)(1.4m)(1.5m)264.0k(2.1m)(1.1m)572.0k98.0k(992.0k)167.0k(779.0k)301.0k1.5m497.0k(1.2m)(1.2m)(1.9m)
show all
USDQ2, 2011

Financial Leverage

1.3 x
Show all financial metrics

Alimera Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

Learn more about our premium products
SecurityScorecard logo

Alimera Sciences Online and Social Media Presence

Alimera Sciences's Trends

Embed Graph

Alimera Sciences Company Culture

  • Overall Culture

    B-

    77/100

  • CEO Rating

    A+

    90/100

  • Compensation

    A

    88/100

Learn more on Comparably

Alimera Sciences News and Updates

May 17, 2021

Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist

ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced the expansion of its leadership team with the appointment of David Dyer, M.D. as chief retina speci…
April 22, 2021

Alimera Sciences to Report First Quarter 2021 Financial Results on Wednesday, April 28, 2021 and Provide Corporate Update

Conference Call to be held Thursday, April 29, 2021 at 9:00am Eastern Time Conference Call to be held Thursday, April 29, 2021 at 9:00am Eastern Time
April 14, 2021

Alimera Sciences Receives $20 Million From Ocumension Therapeutics

ATLANTA, April 14, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announced today that Ocumension Therapeutics (Ocumension), a company focused o…
April 09, 2021

Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021

ATLANTA, April 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that Rick Eiswirth, Pre…
March 02, 2021

Alimera Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

ATLANTA, March 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick E…
February 18, 2021

Alimera Sciences Continues Global Geographic Expansion With Launch of ILUVIEN in Finland for Both Indications

ATLANTA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that ILUVIEN is now available in Finland for diabetic macular edema (…
Show more

Alimera Sciences Blogs

April 28, 2021

Alimera Sciences Announces First Quarter 2021 Financial Results

Alimera Sciences Announces First Quarter 2021 Financial Results
March 17, 2021

Alimera Sciences Continues to Execute on Its Expansion Strategy in Denmark and Luxembourg, and Achieves Extended Reimbursement in Ireland

Alimera Sciences Continues to Execute on Its Expansion Strategy in Denmark and Luxembourg, and Achieves Extended Reimbursement in Ireland
March 11, 2021

Alimera Sciences to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference

Alimera Sciences to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference
February 24, 2021

Alimera Sciences Reports Fourth Quarter and 2020 Results

Alimera Sciences Reports Fourth Quarter and 2020 Results
January 05, 2021

Alimera Sciences to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference

Alimera Sciences to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference
December 09, 2020

Alimera Sciences Announces Launch of ILUVIEN® in the Netherlands

Alimera Sciences Announces Launch of ILUVIEN® in the Netherlands
Show more

 Alimera Sciences Frequently Asked Questions

  • When was Alimera Sciences founded?

    Alimera Sciences was founded in 2003.

  • Who are Alimera Sciences key executives?

    Alimera Sciences's key executives are Ken Greene, Rick Eiswirth and Susan Caballa.

  • How many employees does Alimera Sciences have?

    Alimera Sciences has 122 employees.

  • What is Alimera Sciences revenue?

    Latest Alimera Sciences annual revenue is $50.8 m.

  • What is Alimera Sciences revenue per employee?

    Latest Alimera Sciences revenue per employee is $416.6 k.

  • Who are Alimera Sciences competitors?

    Competitors of Alimera Sciences include BeyondSpring, Biocon and Cipla.

  • Where is Alimera Sciences headquarters?

    Alimera Sciences headquarters is located at 6120 Windward Pkwy #290, Alpharetta.

  • Where are Alimera Sciences offices?

    Alimera Sciences has offices in Alpharetta, Berlin, Dublin 2, Lisboa and in 1 other location.

  • How many offices does Alimera Sciences have?

    Alimera Sciences has 5 offices.